Diagnostic assessment occasionally presents carcinoma of unknown primary site (CUP) with metastatic renalcell carcinoma (mRCC) histologic and immunohistochemical characteristics (CUP-mRCC). We reviewed our single-institution experience and searched the PubMed database, and identified 10 patients treated at our institution; 60% were poor risk patients. Objective response rate was 40%, progression-free survival was 2.5 months, and overall survival was 5.7 months; and the literature search identified 42 CUP-mRCC cases, for a total of 52 cases of CUP-mRCC. Vascular endothelial growth factoretargeted therapy is valid, feasible, and safe in CUP-mRCC, and these patients should thus be identified among CUP patients for specific renal-cell carcinoma therapy. Background: Carcinoma of unknown primary site (CUP) is a heterogenous group of metastatic cancer with no detectable primary tumor site. Diagnostic assessment occasionally presents CUP with metastatic renal-cell carcinoma (mRCC) histologic and immunohistochemical characteristics (CUP-mRCC). Efficacy and toxicity data for vascular endothelial growth factor inhibitor therapies in CUP-mRCC patients are few. Patients and Methods: We retrospectively reviewed consecutive patients with CUP-mRCC at a single institution between 2007 and 2018. Treatment outcomes were assessed from initiation of renal-cell carcinomaespecific therapy, including response rate, progression-free survival, and overall survival. Results: Ten patients with CUP-mRCC were identified. Median age was 64 years. Histologies were clear-cell (30%), papillary type II (20%), and unclassified renal-cell (50%) carcinoma. International Metastatic Renal Cell Carcinoma Database Consortium risk group were favorable, intermediate, and poor in 0, 40%, and 60%, respectively. One patient received empiric first-line chemotherapy. Targeted treatments were pazopanib (n ¼ 7), sunitinib (n ¼ 2), and sorafenib (n ¼ 1). Objective response rate was 40%, progression-free survival was 2.5 months (95% confidence interval, 1.2-3.8), and overall survival was 5.7 months (95% confidence interval, 0-24.0). Stratified for International Metastatic Renal Cell Carcinoma Database Consortium risk, overall survival in intermediate versus poor risk group were 18.6 months and 2.3 months, respectively. Second-line therapy did not result in disease control. No new or unexpected toxicities were observed. Conclusion: CUP-mRCC treated with vascular endothelial growth factoretargeted therapy is valid, feasible, and safe even though these patients had several negative prognostic factors. CUP-mRCC patients should be identified among CUP patients for specific renal-cell carcinoma therapy.
Introduction
Cancer of unknown primary site (CUP) comprises a heterogenous group of metastatic cancer with no detectable primary tumor site, comprising 3% to 5% of all malignancies.
1 CUP has generally a poor outcome, with a median survival between 4 and 12 months. 1, 2 CUP is a diagnosis of exclusion that can be made only after thorough clinical examination, computed tomography of chest, abdomen, and pelvis, and basic blood and biochemical analyses; endoscopies should be performed only according to signs, symptoms, or abnormal laboratory test results. A core needle biopsy of the metastasis is performed, and the sample is assessed by immunohistochemistry (IHC). 1, 3 In recent years, the biopsy sample may also be assessed by molecular analyses. 4, 5 Diagnostic CUP assessment may occasionally result in metastatic renal-cell carcinoma (mRCC) histologic and IHC characteristics (CUP-mRCC). This entity has only rarely been described in the literature. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Renal-cell carcinoma (RCC) is a group of cancers arising from the nephron, where 70% of RCC are clear-cell RCC. Because of mutation in the Von Hippel-Lindau gene, a high amount of vascular endothelial growth factor (VEGF) is produced, resulting in increased angiogenesis, cell growth, metabolism, and immunesuppression. 21 VEGF tyrosine kinase inhibitors or mammalian target of rapamycin (mTOR) are the mainstay therapies for mRCC, including pazopanib, sunitinib, sorafenib, axitinib, cabozantinib, temsirolimus, and everolimus. [22] [23] [24] Also, immune checkpoint inhibitors such as nivolumab and ipilimumab have recently demonstrated benefit, targeting the programmed cell-death 1 (PD-1) and cytotoxic T-lymphocyteeassociated protein 4 (CTLA-4) receptors. 22, 25 In contrast, empiric chemotherapy for CUP has no effect on mRCC. 22 This study assessed patient outcome and adverse effects in consecutive patients with histology and IHC compatible with RCC in a biopsy sample of metastasis in patients with CUP-mRCC.
Patients and Methods
This study was a retrospective assessment of consecutive patients with CUP-mRCC treated at the Department of Oncology, Aarhus University Hospital, from January 19, 2007 , to March 4, 2018. Criteria for inclusion in the study were CUP with no primary tumor in the kidney, a biopsy sample from a metastatic lesion with histology and IHC compatible with RCC, a metastatic pattern consistent with mRCC, and treatment with VEGF/mTOR-targeted therapy (TT). The pathology assessment followed CUP guidelines. 1 CUP-mRCC was a diagnosis made on the basis of a broad IHC panel, excluding all known possible primary lesions, with morphology and staining pattern consistent with RCC. A CUP diagnostic core facility integrating molecular diagnostics and IHC was established July 2016 at Aarhus University Hospital. This hospital has a reference population of approximately 2 million citizens. A total of 21 CUP patients had molecular diagnostic data available between July 2016 and April 2018; of these, one patient had molecular diagnostic data and IHC results consistent with RCC and was included in this study. The methodology has been described previously. 26 Medical records were retrospectively reviewed for patient characteristics, treatment, outcome measures, and adverse events.
Patients were characterized according to 3 widely used prognostic models. The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model comprised 6 risk features 27 :
Karnofsky performance status of < 80%, less than 1 year from diagnosis to oncologic treatment, hypercalcemia, anemia, neutrophilia, and thrombocytosis. 
Results

Clinical Characteristics
We identified 10 CUP patients with histology and IHC compatible with RCC and with no primary tumor at initiation of treatment, treated with VEGF/mTOR TT from 2007 to 2018 at Aarhus University Hospital. These 10 CUP-mRCC patients were identified from 110 CUP patients seen at our institution between 2007 and 2018. One patient was diagnosed with a molecular classifier as a supplement to histology plus IHC, and 9 patients were diagnosed by histology and IHC only. Patients were referred for RCC-specific therapy because of suggestive histology or IHC. Table 1 lists the patient characteristics; Table 2 provides results of the IHC stains used. The median age was 64 years, and 60% of subjects were male. None was in a favorable IMDC or MSKCC prognostic subgroup. Risk allocations were as follows: IMDC model, 40% intermediate and 60% poor; MSKCC model, 70% intermediate and 30% poor; and CUP prognostic model, 40% poor. RCC histology was clear cell (30%), papillary type II (20%), and unclassified (50%). At the time of cutoff, 7 patients (70%) had experienced disease progression and died. One patient stopped TT to allow time for wound healing after an unrelated work accident and died before recovery without resuming therapy. One patient was treated with CUP empiric chemotherapy (paclitaxel/carboplatin) and had stable disease as best response for 2.5 months, but experienced disease progression so therapy was changed to pazopanib on the basis of results from molecular assessment of the biopsy sample. At 12þ months this patient was alive and without disease progression. All 10 patients received a VEGF inhibitor, 7 received pazopanib, 2 were treated with sunitinib, and 1 patient was treated with sorafenib. No patients had a visible primary kidney tumor at the initiation of treatment; in one patient, the primary tumor became visible by repeated computed tomographic assessments during VEGF TT. No other patient ever had a primary site identified.
Patient Outcome
A total of 4 patients (40%) had disease that responded to treatment, including one patient who experienced a complete response lasting 2 months. Four patients (40%) had stable disease. Three patients were changed to second-line everolimus therapy because they experienced disease progression or toxicity from first-line therapy; none of these experienced disease control or remission. The median PFS was 2.5 months (95% CI, 1.2-3.8), measured from start of TT ( Figure 1A ). The median OS was 5.7 months (95% CI, 0-24.0) ( Figure 1B ) from start of TT. Three patients had stable disease and were alive for approximately 1þ to 3þ years at data cutoff. Stratified by IMDC prognostic group, the intermediate subgroup had a median survival of 18.6 months (95% CI, 0-42.2), and the poor subgroup had a median survival of 2.3 months (95% CI, 0.8-7.2).
Safety
All patients experienced adverse events to some extent. The majority of toxicities were grade 1/2 stomatitis, fatigue, or diarrhea (Table 3) . If unacceptable toxicity occurred, the dose was reduced to reach grade 1 toxicity. One patient (10%) discontinued pazopanib as a result of reversible posterior leukoencephalopathy, an extremely rare but known adverse effect; pazopanib was discontinued permanently, and therapy was changed to everolimus. One patient treated with pazopanib had grade 4 liver toxicity with elevated transaminases and bilirubin. After treatment interruption and steroid treatment, liver enzymes normalized, and pazopanib was resumed at a lower dose, with no recurrence of liver toxicity.
Discussion
This assessment of consecutive patients with CUP and mRCC histologic and IHC characteristics (CUP-mRCC) treated with contemporary VEGF TT demonstrated this treatment strategy to be valid, feasible, and safe. This patient group had a high percentage of high-risk features, and only 30% of patients had clear-cell histology, an additional adverse factor. 29 Thus, CUP-mRCC represents an aggressive metastatic malignancy and may serve as a poor prognostic factor per se. In spite of this, responses to RCC treatment were seen in 40% of patients; tumor response is a robust measure of treatment sensitivity. Moreover, 3 of 10 patients were free of progression at > 12 months, which suggests treatment efficacy in some patients. The implication is that CUP-mRCC patients should be identified among CUP patients and referred for RCC-specific therapy.
A recent large study provided benchmark data in mRCC patients with poor risk category treated with TT in phase 2 and 3 clinical trials; PFS was 4 months, response rate 10%, and OS 9 months. 30 Because our study cohort comprised only 10 patients (a small sample size), because most patients did not fulfill the criteria for enrollment onto a clinical trial, and because approximately half of the patients were in the poor risk category, the observed PFS of 2.3 months and OS of 5.7 months were in line with RCC benchmark data. 27, 30 Until recently, is has been controversial whether metastases from RCC without a primary kidney tumor is a true clinical entity. We searched PubMed and identified 13 publications in the scientific literature dealing with CUP-mRCC ( 12 and everolimus (n ¼ 1). 13 Efficacy data showed that 8 (72%) of 11 patients responded to treatment, and 9 (82%) of 11 were alive when the cases were reported, surviving between 6 weeks and 36 months. The risk of selection bias when publishing case reports is evident; there is a risk of selecting cases for publication when treatment was successful rather than unsuccessful. Furthermore, no baseline prognostic values were described. This might explain why our results have a far worse outcome than the case reports. A recent retrospective study of 24 CUP patients with mRCC characteristics treated with TT showed a median OS of 12 months. 20 The disease of these patients was all identified by molecular analyses, in contrast 
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Clinical Genitourinary Cancer February 2019 -e35 to our study, where only a single patient was characterized by molecular diagnostic methods. Thus, a more accurate diagnosis may improve outcome. In line with our findings, the study observed a larger number of papillary and unclassified RCC subtypes, and a subset of patients who experienced long-term benefit from TT. 20 Noneclear-cell histologies, with a high fraction of unclassified RCC, seem predominant in CUP-mRCC. A total of 52 cases of CUP-mRCC have now been described in the literature, and CUPmRCC is surely a true clinical entity, although more research is warranted. New molecular cancer classifier assays have been developed and may advance the diagnostics of CUP-for example, gene expression profiling (pathwork tissue of origin test), the molecular profiling 92-gene reverse transcriptase PCR cancer classification assay (CancerTYPE ID), and epigenetic DNA microarray (EPI-CUP). 4, 5 Importantly, time from biopsy to final report has greatly shortened, and most answers now appear within few weeks, making molecular diagnostic feasible in a real-world clinical setting. Several of the above-mentioned case reports used molecular diagnostic tools after inconclusive IHC diagnostic assessment and identified the tissue of origin, thereby enabling treatment with TT. 10, [12] [13] [14] 19 Molecular profiling is not yet part of standard diagnostic assessment at most institutions. 1 It is unknown why the primary tumor was not found in the kidneys at the time of diagnosis. This may be because mRCC is known for its ability of spontaneous regression of metastatic lesions, although this is rare. 31 In line with this, spontaneous regression of the primary kidney lesion has also been suggested. 17 Further, some CUP-mRCC might comprise a case of an aggressive cancer with early metastasis, where the primary tumor has undergone spontaneous regression or has burned out. In addition, some CUP-mRCC might have metastasized early; the primary tumors were too small for initial detection but became visible on repeated scans during follow-up, as was the case in one of the patients in this study.
Another explanation is that the metastasis we found was actually a primary cancer in rudimentary embryonic mesonephric remnants 15 or was ectopic kidney tissue. 16 This embryonic explanation is well described in testicular cancer, where it is known as extragonadal germ-cell tumors. 32 These tumors with primary tumor in 33 VEGF inhibitors have been the reference standard treatment for mRCC, but recent progress has demonstrated that the checkpoint inhibitors nivolumab plus ipilimumab result in better survival for IMDC poor and intermediate patients compared to sunitinib in the first-line setting, and nivolumab results in better survival compared to everolimus in the second-line setting. Checkpoint inhibitors may thus replace targeted treatment as standard treatment. 34, 35 For CUP patients, a combined IHC and molecular diagnostic assessment seems increasingly important. Accurate diagnosis of CUP-mRCC may prevent unnecessary toxicity and wasted time resulting from ineffective chemotherapy, so these patients may immediately receive treatment with contemporary mRCC therapy.
Limitations to the current study are the small number of patients, the retrospective nature of the study, and the use of only IHC diagnostics in all but one patient. However, to our knowledge, this is the only study in consecutive patients with CUP-mRCC providing MSKCC and IMDC prognostic information, which places the results in context.
In conclusion, CUP-mRCC treated with VEGF TT is valid, feasible, and safe, despite these patients having several negative prognostic factors. CUP-mRCC patients should be identified among CUP patients for specific RCC therapy.
Clinical Practice Points
CUP with RCC histologic and IHC characteristics (CUPmRCC) is a rare entity. CUP-mRCC comprises a larger number of papillary and unclassified RCC subtypes. CUP-mRCC seems to have several poor risk features. Thus, CUP-mRCC may represent a poor prognostic factor per se. CUP-mRCC treated with VEGF TT is valid, feasible, and safe. Disclosure F.D. reports research grants from Pfizer, Novartis, and Ipsen. The other authors have stated that they have no conflict of interest.
